Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Skyworks Solutions Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Skyworks Solutions Inc trades at $76.8 (market cap $18.01B). The key difference: Skyworks Solutions Inc is far larger — about 6.3× Dyne Therapeutics Inc. Common Stock's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Skyworks Solutions Inc for 50 Days on average.
| DYN | SWKS | |
|---|---|---|
Market Cap | $2.86B | $18.01B |
Volume | 3,341,579 | 4,074,606 |
Sector | Health | Technology |
52-Week High | $26.78 | $91.45 |
52-Week Low | $14.60 | $52.50 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $2.18B | $17.89B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Skyworks Solutions (SWKS) trades at $76.89, up 2.93% with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.10M. The pending Qorvo merger dominates news coverage, with analysts projecting significant synergies. Current valuation metrics include a P/E of 39.68 and P/S of 2.87, while cash flow trends show recent negative net cash flow of -$207.30M.
The investment outlook balances merger synergies against fundamental deterioration. Analyst consensus favors Buy (60%) with a $79.70 price target, but declining profitability and bearish technicals suggest caution. Key risks include integration challenges with Qorvo and ongoing margin pressure, while the RSI near 18 indicates potential oversold conditions for tactical opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
